Four-month rifapentine regimen with moxifloxacin noninferior for TB
One-third of patients hospitalized with severe COVID-19 still have lung changes after a year
6 May 2021Patents not ‘limiting factor’ for vaccine production: BioNTech
6 May 2021Four-month rifapentine regimen with moxifloxacin noninferior for TB
(HealthDay)—A four-month rifapentine-based regimen containing moxifloxacin is noninferior to a standard six-month regimen for treatment of tuberculosis, according to a study published in the May 6 issue of the New England Journal of Medicine.
